ODT vs. IR [Regulatives / Guidelines]

posted by mittyri  – Russia, 2014-03-08 16:24 (4496 d 14:37 ago) – Posting: # 12580
Views: 5,179

Dear All,

could you you help me with EMA guideline understanding at this part:

"If the ODT test product is an extension to another oral formulation, a 3-period study is recommended in order to evaluate administration of the orodispersible tablet both with and without concomitant fluid intake. However, if bioequivalence between ODT taken without water and reference formulation with water is demonstrated in a 2-period study, bioequivalence of ODT taken with water can be assumed."

What does it mean?
"We recommend you to perform 3-period study. By the way you can perform simple 2-period study and it's enough"

Who will perform complex 3-period study in the presence of simple solution?:confused:

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
303 visitors (0 registered, 303 guests [including 20 identified bots]).
Forum time: 08:02 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5